MOMENTUM 3 and UNOS registry propensity-matched comparison
Comparative analysis between HeartMate 3 Left Ventricular Assist Device (LVAD) and heart transplantation (HTx) in heart failure patients under 50, using data from the MOMENTUM 3 trial and the UNOS registry.
In advanced heart failure patients <50, 2-year outcomes showed:

From time of implant or transplantation, HeartMate 3 LVAD and HTx patients have equivalent survival of 91%.

From time of implant or HTx listing, HeartMate 3 LVAD patients have a 12% decreased risk of death compared to risk of death or delisting* for HTx candidates.
*delisted for worsening health
MAT-2506017 v2.0
Stay Connected